You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)與Anwita簽署許可協議
格隆匯 09-30 06:17

格隆匯 9 月 30日丨君實生物(01877.HK)發佈公告,公司擬與Anwita Biosciences, Inc.(“Anwita”)簽署《許可協議》,Anwita授予公司在許可區域(包括中國大陸、中國香港、中國澳門和中國台灣)單獨使用《許可協議》中約定的Anti-HSA-IL-2Nα系列產品及相關的ANWITA技術和知識產權或與公司專有產品結合使用的獨佔許可。該事項尚需提交股東於公司2020年第三次臨時股東大會審議。

Anwita授予公司在許可區域單獨使用《許可協議》中約定的Anti-HSA-IL2Nα系列產品及相關的ANWITA技術和知識產權,或與公司專有產品結合使用的獨佔許可,許可產品包括IL-2Nα蛋白、Anti-HSA-IL-2Nα融合蛋白及衍生物,公司在許可區域內對許可產品進行研發及商業化。此外,公司有權對相關授權進行分許可,並擁有在許可區域外開展臨牀試驗的非獨佔性權利。公司將向Anwita支付200萬美元首付款。 公司將根據研發及商業化進度向Anwita支付累計不超過8600萬美元的里程碑付款。

公告表示,Anwita在細胞因子領域持續的創新能力,其中包括對腫瘤、自身免疫疾病的多個改良細胞因子藥物克服了傳統細胞因子藥物毒性大、半衰期短的缺點,具有一定技術優勢,與公司在腫瘤、自身免疫疾病領域有較大的協同價值。本次交易有利於豐富公司在癌症治療領域的研發管線,完善公司的市場佈局,為市場尚未滿足的臨牀需求提供治療選擇,將對公司的持續經營產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account